

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 01 November 2000 (01.11.00)	
International application No. PCT/US00/08519	Applicant's or agent's file reference OCR-1001
International filing date (day/month/year) 30 March 2000 (30.03.00)	Priority date (day/month/year) 31 March 1999 (31.03.99)
Applicant CAPPELLO, Michael et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:29 September 2000 (29.09.00)☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Charlotte ENGER Telephone No.: (41-22) 338.83.38
--	--

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To: MARY M. KRINSKY
79 TRUMBULL STREET
NEW HAVEN CT 06511-3708


PCT/PCT Rec'd 25 SEP 2001

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

Date of Mailing (day/month/year) 05 JUL 2000	
Applicant's or agent's file reference OCR-1001	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US00/08519	International filing date (day/month/year) 30 MARCH 2000
Applicant YALE UNIVERSITY	

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19:
 The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):
When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.
Where? Directly to the International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 740.14.35
 For more detailed instructions, see the notes on the accompanying sheet.
2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
 - ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
 - ☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.
4. **Further action(s):** The applicant is reminded of the following:
 - Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.
 - Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).
 - Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer HOLLY SCHNIZER 
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

(See notes on accompanying sheet)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference OCR-1001	<div style="display: flex; justify-content: space-between;"> <div style="text-align: center;">FOR FURTHER ACTION</div> <div style="font-size: small;">see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5</div> </div>	
International application No. PCT/US00/08519	International filing date (day/month/year) 30 MARCH 2000	(Earliest) Priority Date (day/month/year) 30 MARCH 1999
Applicant YALE UNIVERSITY		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (See Box II).

4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. 1

☒ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/08519

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 1/00, 14/00; A61K 38/00

US CL : 514/2, 822; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 822; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y --- A	WO 95/12615 A1 (UNIVERSITY OF NOTTINGHAM) 11 May 1995 (11/05/1995), see entire document, especially p. 11, claim 2, p. 12, claim 7, and Figure 4.	12 and 16-19 ----- 1-20
Y --- A	FURMIDGE et al. The anti-haemostatic strategies of the human hookworm <i>Necator americanus</i> . Parasitology. 1995, Vol. 112, pages 81-87, especially page 84, figure 3, and page 86.	12, 14, and 16-19 ----- 1-20

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

14 JUNE 2000

Date of mailing of the international search report

05 JUL 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

HOLLY SCHNIZER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08519

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN (MEDLINE, BIOSIS, CAPLUS); EAST; search terms: GPIIb/IIIa, GPIa/IIa, fibrinogen, collagen, ancylostoma duodenale, ancylostoma ceylanicum, necator americanus, ancylostoma caninum, hookworm, platelet inhibition, epinephrine, thrombin, ADP, apyrase.

PTO/PST Rec'd 25 SEP 2001

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITYTo:
MARY M. KRINSKY
79 TRUMBULL STREET
NEW HAVEN, CT 06511-3708

PCT

AUG 22 2001
hul.

WRITTEN OPINION

(PCT Rule 66)

Applicant's or agent's file reference		Date of Mailing (day/month/year)	20 AUG 2001
OCR-1001		REPLY DUE	within 1 months/days from the above date of mailing
International application No.	International filing date (day/month/year)	Priority date (day/month/year)	
PCT/US00/08519	30 March 2000 (30.03.2000)	31 March 1999 (31.03.1999)	
International Patent Classification (IPC) or both national classification and IPC			
IPC(7): C07K 1/00, 14/00; A61K 38/00 and US Cl.: 514/2, 822; 530/350			
Applicant			
YALE UNIVERSITY			

- This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.
- This opinion contains indications relating to the following items:

- ☒ Basis of the opinion
- ☐ Priority
- ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Lack of unity of invention
- ☒ Reasoned statement under Rule 66.2 (a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Certain documents cited
- ☐ Certain defects in the international application
- ☐ Certain observations on the international application

- The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. ~~The applicant may, before the expiration of that time limit, request this Authority to grant an extension. See rule 66.2(d).~~

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

- The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 30 July 2001 (30.07.2001)

Name and mailing address of the IPEA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703)305-3230

Authorized officer

Stephen Tu

Telephone No. 703-305-3130

TERRY J. DEY
PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600

WRITTEN OPINION

International application No.

PCT/US00/08519

I. Basis of the opinion

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed
- ☒ the description:
 - pages 1-25, as originally filed
 - pages NONE, filed with the demand
 - pages NONE, filed with the letter of _____
- ☒ the claims:
 - pages 26 and 27, as originally filed
 - pages NONE, as amended (together with any statement) under Article 19
 - pages NONE, filed with the demand
 - pages NONE, filed with the letter of _____
- ☒ the drawings:
 - pages 1-5, as originally filed
 - pages NONE, filed with the demand
 - pages NONE, filed with the letter of _____
- ☒ the sequence listing part of the description:
 - pages 1-2, as originally filed
 - pages NONE, filed with the demand
 - pages NONE, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written opinion was drawn on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages NONE
- ☐ the claims, Nos. NONE
- ☐ the drawings, sheets/fig NONE

5. ☐ This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed."

WRITTEN OPINION

International application No.
PCT/US00/08519

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims 1-20	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims 1-11, 13, 15, 20	YES
	Claims <u>12, 14, 16-19</u>	NO
Industrial Applicability (IA)	Claims 1-20	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-20 meet the criteria for novelty under PCT Article 33(2), because the prior art does not disclose the polypeptide of SEQ ID NO:2 or methods of treatment to inhibit platelet function utilizing the polypeptide, as claimed by Applicants.

Claims 1-11, 13, 15, and 20 meet the criteria for novelty under PCT Article 33(3), because the prior art does not teach the polypeptide of SEQ ID NO:2 or methods of treatment to inhibit platelet function utilizing the polypeptide, as set forth in these claims.

Claims 12, 14, and 16-19 lack an inventive step under PCT Article 33(3) as being obvious over PRITCHARD et al., WO95/12615 in view of FURMIDGE et al., (Parasitology (1995) 112: 81-87). PRITCHARD et al. teaches the pharmaceutical use of derivatives of excretory-secretory (ES) products of *Necator americanus*, particularly as an inhibitor of platelet aggregation. However the reference does not teach or suggest mechanism by which these proteins inhibit platelet aggregation. FURMIDGE et al. teaches mechanisms by which the ES products of *N. Americanus* inhibit platelet aggregation. Specifically, the references indicates that the proteins interfere with the interaction of fibrinogen with platelet alIbB3, which Applicant has referred to as GPIIb/IIIa.

Claims 1-20 meet the criteria for industrial applicability as defined by PCT Article 33(4).

----- NEW CITATIONS -----
NONE

WRITTEN OPINION

International application No.
PCT/US00/08519

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

TIME LIMIT:

The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.

091937555

PATENT COOPERATION TREATY

PCT

REC'D 15 MAR 2002

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
OCR-1001	International filing date (day/month/year)	Priority date (day/month/year)
International application No.	30 March 2000 (30.03.2000)	31 March 1999 (31.03.1999)
PCT/US00/08519	International Patent Classification (IPC) or national classification and IPC	
IPC(7): C07K 1/00, 14/00; A61K 38/00 and US Cl.: 514/2, 822; 530/350		
Applicant		
YALE UNIVERSITY		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
29 September 2000 (29.09.2000)	26 February 2002 (26.02.2002)
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized Officer Chin-Min Kuo
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/IPEA:409 (cover sheet) July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/08519

I. Basis of the report1. With regard to the **elements** of the international application:*

- ☒ the international application as originally filed.
- ☒ the description:
pages 1-25 as originally filed
pages NONE filed with the demand
pages NONE filed with the letter of _____.
- ☒ the claims:
pages 26 and 27 as originally filed
pages NONE as amended (together with any statement) under Article 19
pages NONE filed with the demand
pages NONE filed with the letter of _____.
- ☒ the drawings:
pages 1-5 as originally filed
pages NONE filed with the demand
pages NONE filed with the letter of _____.
- ☒ the sequence listing part of the description:
pages 1-2 as originally filed
pages NONE filed with the demand
pages NONE filed with the letter of _____.

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig NONE

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US00/08519

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)

Claims 1-20

YES

Claims NONE

NO

Inventive Step (IS)

Claims 1-11, 13, 15 and 20

YES

Claims 12, 14, 16-19

NO

Industrial Applicability (IA)

Claims 1-20

YES

Claims NONE

NO

2. CITATIONS AND EXPLANATIONS

Claims 1-20 meet the criteria for novelty under PCT Article 33(2), because the prior art does not disclose the polypeptide of SEQ ID NO:2 or methods of treatment to inhibit platelet function utilizing the polypeptide, as claimed by Applicants.

Claims 1-11, 13, 15 and 20 meet the criteria for novelty under PCT Article 33(3), because the prior art does not teach the polypeptide of SEQ ID NO:2 or methods of treatment to inhibit platelet function utilizing the polypeptide, as set forth in these claims.

Claims 12, 14 and 16-19 lack an inventive step under PCT Article 33(3) as being obvious over PRITCHARD et al. (WO 95/12615) in view of FURMIDGE et al. (Parasitology (1995) 112:81-87). PRITCHARD et al. teach the pharmaceutical use of derivatives of excretory-secretory(ES) products of *Necator americanus*, particularly as an inhibitor of platelet aggregation. However, the reference does not teach or suggest mechanism by which these proteins inhibit platelet aggregation. FURMIDGE et al. teach mechanisms by which the ES products of *N. americanus* inhibit platelet aggregation. Specifically, the references indicate that the proteins interfere with the interaction of fibrinogen with platelet aIIbB3, which Applicant has referred to as GPIIb/IIIa.

Claims 1-20 meet the criteria for industrial applicability as defined by PCT Article 33(4).

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/08519

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07K 1/00, 14/00; A61K 38/00

US CL :514/2, 822; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 822; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y --- A	WO 95/12615 A1 (UNIVERSITY OF NOTTINGHAM) 11 May 1995 (11/05/1995), see entire document, especially p. 11, claim 2, p. 12, claim 7, and Figure 4.	12 and 16-19 ----- 1-20
Y --- A	FURMIDGE et al. The anti-haemostatic strategies of the human hookworm <i>Necator americanus</i> . Parasitology. 1995, Vol. 112, pages 81-87, especially page 84, figure 3, and page 86.	12, 14, and 16-19 ----- 1-20

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 JUNE 2000

Date of mailing of the international search report

05 JUL 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

HOLLY SCHNIZER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08519

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN (MEDLINE, BIOSIS, CAPLUS), EAST; search terms: GPIIb/IIIa, GPIa/IIa, fibrinogen, collagen, ancylostoma duodenale, ancylostoma ceylanicum, necator americanus, ancylostoma caninum, hookworm, platelet inhibition, epinephrine, thrombin, ADP, apyrase.